Catalyst Dossier · compiled by CeliA 🧫
TherapeuticsMD, Inc. (TXMD)
Pharmaceutical Preparations · market cap $9M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-09-11 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
TherapeuticsMD (TXMD) is a micro-cap pharmaceutical company with a $24M market cap, 1 reported employee, and $8.4M in cash. The company's pipeline listing is unusually broad and eclectic — spanning dozens of assets across unrelated therapeutic areas — suggesting the disclosed pipeline reflects a data aggregation artifact or licensing/tracking portfolio rather than a wholly-owned internal pipeline. Revenue has collapsed from ~$87M in 2021 to ~$3M in 2025, and the company carries a net cash position of $8.4M against ongoing operating losses.
The catalyst path
- 2026-09-11 (est.)Phase 3 · Brepocitinib PO QDimp 9/10
- 2026-09-15 (est.)Phase 2 · DPI-386 Nasal Gelimp 7/10
- 2026-10-01 (est.)Phase 2 · Rhu-pGSNimp 7/10
- 2026-10-15 (est.)Phase 2 · YL201 for Injectionimp 7/10
- 2026-10-15 (est.)Phase 3 · BHV-7000imp 9/10
- 2026-11-15 (est.)Phase 2 · ABT-101imp 7/10
- 2026-11-30 (est.)Phase 3 · GS1191-0445 injectionimp 9/10
- 2026-11-30 (est.)Phase 2 · RNK08954imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| KarXT | Phase 3 | Psychosis Associated With Alzheimer's Disease |
| ATI-450 | Phase 2 | Hidradenitis Suppurativa |
| PTG-300 | Phase 2 | Polycythemia Vera |
| enclomiphene citrate | Phase 3 | Effect of Treatment on Bone Mineral Density |
| REL-1017 | Phase 3 | Major Depressive Disorder |
| Dexycu | Phase 3 | Inflammation |
| ETC-1002 | Phase 3 | Hypercholesterolemia |
| MSDC-0602K | Phase 2 | Non-alcoholic Fatty Liver Disease |
| Human platelets | Phase 3 | Cardiac Surgery |
| Pegtibatinase | Phase 3 | Homocystinuria |
| Allo-QuadCAR01-T | Phase 2 | Lymphoma Diffuse Large B-cell |
| 188-0551 Solution | Phase 2 | Plaque Psoriasis |
| IG3018 | Phase 2 | Hyperuricemia |
| YL201 for Injection | Phase 2 | Advanced Solid Tumor |
| 5 mg Serlopitant Tablets | Phase 2 | Pruritus |
| 3.2 mg intranasal carbetocin | Phase 3 | Prader-Willi Syndrome |
| Halobetasol Propionate Lotion 0.05% | Phase 2 | Psoriasis |
| XIAFLEX / XIAPEX | Phase 3 | Dupuytren's Contracture |
| OPN-305 | Phase 2 | Myelodysplastic Syndrome |
| Gene Therapy product:vMCO-I | Phase 2 | Retinitis Pigmentosa |
Price & technical context
3-month
+8.1%
6-month
+1.3%
12-month
+105.4%
52-wk range
$1.04–$2.77
vs 50-day MA
+10.4%
vs 200-day MA
+11.5%
Realized vol
74.9%
Max drawdown
-62.6%
Daily closes through 2026-08-26. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TXMD (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.